11:34 AM EST - BioVaxys Technology Corp : Announced it has received a Notice of Allowance from the Japanese Patent Office for a Patent for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX™. This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc. This Patent has already been issued in the US, and is currently pending in the EU. BioVaxys Technology Corp
shares C.BIOV are trading unchanged at $0.09.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACNX&qmodStoryID=7178009087165493
